Prothena Corp Public (PRTA) Income from Continuing Operations (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Income from Continuing Operations came in at 32721000.0 in Q1 2026, up 154.36% year-on-year from 12864135.14 in Q1 2025, and up 251.89% quarter-over-quarter from 21542000.0 in Q4 2025.
Prothena Corp Public (PRTA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Prothena Corp Public's Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 32721000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 154.36% year-over-year to 32721000.0 in Q1 2026; TTM through Mar 2026 was 151100000.0, a 36.91% decrease from a year earlier, with the FY2025 full-year figure at 244092000.0, down 99.57% from the prior year.
- Income from Continuing Operations improved to 32721000.0 in Q1 2026 per PRTA's latest filing, from 21542000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 66847000.0 in Q2 2024 and bottomed at 125767000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 45717000.0 (2022), against an average of 35157176.47.
- Across the five-year window, Income from Continuing Operations slumped 1162.78% in 2023 and jumped 222.43% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 6349000.0 in 2022, then slumped by 1162.78% to 67476000.0 in 2023, then rose by 14.07% to 57981000.0 in 2024, then soared by 62.85% to 21542000.0 in 2025, then jumped by 251.89% to 32721000.0 in 2026.
- Per Business Quant, the three latest PRTA Income from Continuing Operations figures stand at 32721000.0 (Q1 2026), 21542000.0 (Q4 2025), and 36512000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Prothena Corp Public | 467.80 Mn | 138.33 Mn | - | 32.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.54 Mn |
| Sep 30, 2025 | -36.51 Mn |
| Jun 30, 2025 | -125.77 Mn |
| Mar 31, 2025 | -60.20 Mn |
| Dec 31, 2024 | -57.98 Mn |
| Sep 30, 2024 | -59.04 Mn |
| Jun 30, 2024 | 66.85 Mn |
| Mar 31, 2024 | -72.24 Mn |
| Dec 31, 2023 | -67.48 Mn |
| Sep 30, 2023 | 21.92 Mn |
| Jun 30, 2023 | -54.60 Mn |
| Mar 31, 2023 | -46.88 Mn |
| Dec 31, 2022 | 6.35 Mn |
| Sep 30, 2022 | -45.72 Mn |
| Jun 30, 2022 | -41.27 Mn |
| Mar 31, 2022 | -36.29 Mn |
| Dec 31, 2021 | -33.14 Mn |
| Sep 30, 2021 | 109.25 Mn |
| Jun 30, 2021 | 27.60 Mn |